Aucun commentaire a l international ..??

Lire

DAILY DIVE

Dec.​ 16,​ 2020 | Today's news and insights for biopharma leaders

BROUGHT TO YOU BY — ZS How AI Is Enabling Better Patient InsightsA look at how UCB is utilizing AI-enabled dynamic targeting to collect better insights and get solutions into the hands of the patients who need them. Read now. Pharmacquired: What a surprise deal does for AstraZeneca and Alexion

The $39 billion tie-up between the two companies sparked questions about whether Alexion could have sold for more. Yet, it doesn't look like rival bidders stood in AstraZeneca's way.

With trial plans, Novo wagers its diabetes drug can help treat Alzheimer's

Similar diabetes drugs from Novo have shown signs of promise in treating dementia. The Danish biotech is now putting that hypothesis to the test.

Sage replaces CEO Jonas with Alnylam veteran Greene

Jeff Jonas, who has been with Sage since 2013, will stay on as the neuroscience biotech's chief innovation officer.

SPONSORED CONTENT BY SARTORIUSAre you GLP/GMP compliant when it comes to pipetting? Practical guide – pipetting guidelines to ensure compliance with GLP and GMP. Download now! Gilead hands back some rights to key drug from Galapagos deal

The drug, known as filgotinib, recently hit a setback in the U.S., prompting Gilead to lose confidence that it can gain approval or compete against rival medicines in rheumatoid arthritis.

Read more news FEATURED RESOURCESFROM: PDA Prepare for 2021 with Expert Training from PDA Designing and Presenting GXP Training Programs to Meet PDA RequirementsFundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing FacilitiesPDA Onsite Training: Customized, Convenient, and Cost Effective FROM OUR LIBRARY WEBINAR - ON DEMANDTransforming the Pharma Supply Chain with Blockchain By studioID WEBINAR - ON DEMANDTaking the First Step Toward a Critical Evolution of Pharma’s Commercial Model By studioID WEBINAR - ON DEMANDHow AI Can Optimize Your Drug Supply Strategy By studioID WEBINAR - ON DEMANDAdvancing Single-Use Solutions for End-To-End Purity and Reliability By studioID View all resources WHAT WE'RE READING THE NEW YORK TIMES U.S. and Pfizer Are Negotiating Deal for More Vaccine Doses Next Year FIERCEPHARMA Novartis' heart failure med Entresto wins FDA panel backing for bigger patient group—but just how much bigger? REUTERS WHO vaccine scheme risks failure, leaving poor countries no COVID shots until 2024 ENDPOINTS NEWS After leaving Wall Street to launch a gene therapy upstart, Rachel McMinn nabs $115M to drive her first candidate to the clinic Suggest a story we should read DIVE INTO A TOPIC

Pharma Biotech FDA

Clinical Trials Deals

Drug Pricing Gene Therapy